Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/303% below fair value
$73.01−4.66 (-6.00%)
Close on Nov 20, 2026Market cap $3.20BP/E –Yield 0.00%
Tarsus Pharmaceuticals gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $161.80M | – |
| Q1 FY2026 | Mar 31, 2026 | $152.66M | +6006.3% |
| Q2 FY2025 | Jun 30, 2025 | $96.42M | – |
| Q1 FY2025 | Mar 31, 2025 | $73.12M | +395.6% |
| Q2 FY2023 | Jun 30, 2023 | $0 | -100.0% |
| Q1 FY2023 | Mar 31, 2023 | $2.50M | +112.8% |
| Q3 FY2022 | Sep 30, 2022 | $0 | – |
| Q2 FY2022 | Jun 30, 2022 | $14.76M | – |
| Q1 FY2022 | Mar 31, 2022 | $506.00K | – |
| Q3 FY2021 | Sep 30, 2021 | $1.18M | – |
See a number that looks wrong?